Bavdegalutamide

Bavdegalutamide
Clinical data
Other names	ARV-110
Identifiers
	IUPAC name N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide;
CAS Number	2222112-77-6 ;
PubChem CID	134414307 ;
DrugBank	DB19032 ;
ChemSpider	110415899 ;
UNII	H6NYM0V650 ;
KEGG	D12316 ;
ChEMBL	ChEMBL4862963 ;
Chemical and physical data
Formula	C41H43ClFN9O6
Molar mass	812.30 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1CC(CCC1NC(=O)C2=NN=C(C=C2)N3CCC(CC3)CN4CCN(CC4)C5=C(C=C6C(=C5)C(=O)N(C6=O)C7CCC(=O)NC7=O)F)OC8=CC(=C(C=C8)C#N)Cl;
	InChI InChI=InChI=1S/C41H43ClFN9O6/c42-31-19-28(4-1-25(31)22-44)58-27-5-2-26(3-6-27)45-38(54)33-7-9-36(48-47-33)51-13-11-24(12-14-51)23-49-15-17-50(18-16-49)35-21-30-29(20-32(35)43)40(56)52(41(30)57)34-8-10-37(53)46-39(34)55/h1,4,7,9,19-21,24,26-27,34H,2-3,5-6,8,10-18,23H2,(H,45,54)(H,46,53,55); Key:CLCTZVRHDOAUGJ-UHFFFAOYSA-N;

Last updated September 13, 2025

Bavdegalutamide is an experimental proteolysis targeting chimera that functions as a androgen receptor degrader.^[1] It is being developed to treat metastatic castration-resistant prostate cancer.^[2]^[3]^[4]

References

↑ "Bavdegalutamide". PubChem. U.S. National Library of Medicine. Retrieved 2024-10-31.
↑ Shore ND, Shen J, Devitt ME, Lu H, Alicea J, Parameswaran J, et al. (June 2022). "Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer" . Journal of Clinical Oncology. 40 (16_suppl): TPS5106. doi:10.1200/JCO.2022.40.16_suppl.TPS5106. ISSN 0732-183X.{{cite journal}}: CS1 maint: article number as page number (link)
↑ "Bavdegalutamide - Arvinas". AdisInsight. Springer Nature Switzerland AG.
↑ Jia X, Han X (February 2023). "Targeting androgen receptor degradation with PROTACs from bench to bedside". Biomedicine & Pharmacotherapy. 158 114112. doi: 10.1016/j.biopha.2022.114112 . PMID 36508999.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Bavdegalutamide". PubChem. U.S. National Library of Medicine. Retrieved 2024-10-31.

[2] Shore ND, Shen J, Devitt ME, Lu H, Alicea J, Parameswaran J, et al. (June 2022). "Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer" . Journal of Clinical Oncology. 40 (16_suppl): TPS5106. doi:10.1200/JCO.2022.40.16_suppl.TPS5106. ISSN 0732-183X.{{cite journal}}: CS1 maint: article number as page number (link)

[3] "Bavdegalutamide - Arvinas". AdisInsight. Springer Nature Switzerland AG.

[Jia_2023-4] Jia X, Han X (February 2023). "Targeting androgen receptor degradation with PROTACs from bench to bedside". Biomedicine & Pharmacotherapy. 158 114112. doi: 10.1016/j.biopha.2022.114112 . PMID 36508999.

[1]

[2]

[3]

[4]